entertainment -WSS

entertainment

author：comprehensive 2025-10-01 22:50:50 - browse：16325

The ability of cancer cells to move and spread depends on actin-rich core structures such as the podosomes (yellow) shown here in melanoma cells. Cell nuclei (blue), actin (red), and an actin regulator (green) are also shown. — Metastatic melanoma cells Julio C. Valencia,/NCI Center for Cancer Research

Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from Iovance, is the first cell therapy approved for a solid tumor.

“It’s so exciting and gratifying,” said Allison Betof Warner, a cell therapy researcher and physician at Stanford University who has worked on Amtagvi. “This is a game-changing moment for our field. We’ve seen huge success of cellular therapy for hematologic malignancies, and we’ve yet to capitalize on that for solid tumors. This is hopefully the first of many to come.”

In a Phase 2 clinical trial, titled C-144-01, 153 patients who had already been on a median of three prior lines of therapy received lifileucel, and 31% of them responded to therapy. “These are in very late line patients. They’ve exhausted every standard care option,” Betof Warner said. “The most promising part of this therapy for me is that 42% of patients who responded were still responding for 18 months or longer. It’s truly incredible.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Man who had jail sentence commuted by Trump arrested again

WSS

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Stanford updates investigation of president’s past research

Steward Health Care Massachusetts hospitals face fiscal disaster

TikTok cracks down on users posting about weight loss drugs

Plane’s emergency slide plummets from sky, hits Chicago home

focus

entertainment

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Ebola: Gilead Sciences antiviral shows promise as new treatment

Alkermes shareholders re

Boston's new lab space is opening empty

Anesthesiologist group: stop taking Ozempic before surgery

'Reaching a detente': STAT's Helen Branswell on covering Covid

Psychedelics group wrestles with new pharma identity

HHS secretary Becerra pressed on Change HealthCare cyberattack

BioMarin wins approval for gene therapy to treat hemophilia A

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

focus

Celebrate National Dole Whip Day for 3 days this week at Disney

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

WuXi out of biotech trade group, U.S. and China relations to blame

Seattle police shoot person suspected in downtown stabbing

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

'Reaching a detente': STAT's Helen Branswell on covering Covid

explore

knowledge

Wikipedia

leisure time